Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PNRC2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PNRC2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PNRC2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PNRC2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PNRC2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PNRC2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PNRC2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00001844 | Prostate | BPH | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 14/3107 | 37/18723 | 1.58e-03 | 9.23e-03 | 14 |
GO:000640217 | Prostate | Tumor | mRNA catabolic process | 87/3246 | 232/18723 | 1.56e-13 | 1.73e-11 | 87 |
GO:000640117 | Prostate | Tumor | RNA catabolic process | 94/3246 | 278/18723 | 1.77e-11 | 1.25e-09 | 94 |
GO:000095615 | Prostate | Tumor | nuclear-transcribed mRNA catabolic process | 46/3246 | 112/18723 | 2.80e-09 | 1.17e-07 | 46 |
GO:003465516 | Prostate | Tumor | nucleobase-containing compound catabolic process | 112/3246 | 407/18723 | 1.61e-07 | 4.02e-06 | 112 |
GO:004670014 | Prostate | Tumor | heterocycle catabolic process | 117/3246 | 445/18723 | 1.11e-06 | 2.10e-05 | 117 |
GO:004427015 | Prostate | Tumor | cellular nitrogen compound catabolic process | 118/3246 | 451/18723 | 1.30e-06 | 2.39e-05 | 118 |
GO:190136114 | Prostate | Tumor | organic cyclic compound catabolic process | 124/3246 | 495/18723 | 7.37e-06 | 1.10e-04 | 124 |
GO:001943914 | Prostate | Tumor | aromatic compound catabolic process | 118/3246 | 467/18723 | 7.92e-06 | 1.17e-04 | 118 |
GO:000018412 | Prostate | Tumor | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 16/3246 | 37/18723 | 2.07e-04 | 1.79e-03 | 16 |
GO:000640226 | Thyroid | HT | mRNA catabolic process | 40/1272 | 232/18723 | 4.42e-08 | 2.89e-06 | 40 |
GO:000640126 | Thyroid | HT | RNA catabolic process | 41/1272 | 278/18723 | 2.20e-06 | 7.82e-05 | 41 |
GO:00001848 | Thyroid | HT | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 10/1272 | 37/18723 | 1.29e-04 | 2.07e-03 | 10 |
GO:000095620 | Thyroid | HT | nuclear-transcribed mRNA catabolic process | 18/1272 | 112/18723 | 5.33e-04 | 6.37e-03 | 18 |
GO:003465524 | Thyroid | HT | nucleobase-containing compound catabolic process | 45/1272 | 407/18723 | 8.67e-04 | 9.20e-03 | 45 |
GO:004670020 | Thyroid | HT | heterocycle catabolic process | 47/1272 | 445/18723 | 1.76e-03 | 1.58e-02 | 47 |
GO:001943920 | Thyroid | HT | aromatic compound catabolic process | 48/1272 | 467/18723 | 2.74e-03 | 2.25e-02 | 48 |
GO:190136120 | Thyroid | HT | organic cyclic compound catabolic process | 50/1272 | 495/18723 | 3.22e-03 | 2.55e-02 | 50 |
GO:004427024 | Thyroid | HT | cellular nitrogen compound catabolic process | 46/1272 | 451/18723 | 3.83e-03 | 2.84e-02 | 46 |
GO:0006401112 | Thyroid | PTC | RNA catabolic process | 163/5968 | 278/18723 | 2.13e-20 | 3.27e-18 | 163 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PNRC2 | SNV | Missense_Mutation | novel | c.334N>G | p.Ser112Gly | p.S112G | Q9NPJ4 | protein_coding | deleterious(0.02) | probably_damaging(0.953) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
PNRC2 | SNV | Missense_Mutation | novel | c.340N>C | p.Trp114Arg | p.W114R | Q9NPJ4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
PNRC2 | SNV | Missense_Mutation | novel | c.301N>T | p.Pro101Ser | p.P101S | Q9NPJ4 | protein_coding | deleterious(0.03) | benign(0.144) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD |
PNRC2 | SNV | Missense_Mutation | novel | c.139C>T | p.His47Tyr | p.H47Y | Q9NPJ4 | protein_coding | tolerated(0.27) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PNRC2 | SNV | Missense_Mutation | novel | c.256N>G | p.Lys86Glu | p.K86E | Q9NPJ4 | protein_coding | tolerated(0.78) | benign(0.201) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
PNRC2 | SNV | Missense_Mutation | novel | c.25N>C | p.Ile9Leu | p.I9L | Q9NPJ4 | protein_coding | tolerated(0.14) | benign(0.003) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PNRC2 | SNV | Missense_Mutation | novel | c.392N>C | p.Leu131Pro | p.L131P | Q9NPJ4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
PNRC2 | SNV | Missense_Mutation | novel | c.185N>A | p.Gly62Glu | p.G62E | Q9NPJ4 | protein_coding | tolerated(0.76) | probably_damaging(0.999) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PNRC2 | SNV | Missense_Mutation | novel | c.185N>T | p.Gly62Val | p.G62V | Q9NPJ4 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BC-A3KG-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PNRC2 | SNV | Missense_Mutation | novel | c.111N>C | p.Lys37Asn | p.K37N | Q9NPJ4 | protein_coding | tolerated(0.08) | benign(0.16) | TCGA-67-3771-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |